Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813527 · ClinicalTrials.gov registry record · Phase 2
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
NCT00813527 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 213 participants.
The verdict
NCT00813527, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
Interventions
- DRUG Fenofibrate
- DRUG Lapaquistat acetate and fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813527
The ClinicalTrials.gov registry entry for NCT00813527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fenofibrate is the first listed.
NCT00813527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00813527 about?
NCT00813527 is a clinical study titled "Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels". The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
What is the current status of trial NCT00813527?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2006-02. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00813527?
The interventions under investigation include: Fenofibrate (DRUG), Lapaquistat acetate and fenofibrate (DRUG).
Who is sponsoring clinical trial NCT00813527?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.